Abstract
Systemic sclerosis is an autoimmune disease associated with widespread fibrosis in skin and internal organs. The extent of skin involvement affects quality of life and an improvement in skin thickening predicts better survival.1 Moreover, skin involvement is the primary or secondary outcome in many systemic sclerosis clinical trials. Currently, the extent of skin fibrosis is measured using a palpitation-based, semi-quantitative scoring system called the modified Rodnan skin score (mRSS). Although the mRSS is a validated outcome measure, it requires extensive training and has a high inter-observer variability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
